#USA #New York #Pomerantz LLP #Bath & Body Works #BBWI

Investor Alert: Class Action Lawsuit Filed Against Bath & Body Works

The Pomerantz Law Firm has recently announced the filing of a class action lawsuit against Bath & Body Works, Inc. (often referred to as the "Company") under the stock symbol BBWI. This significant legal step is aimed at addressing allegations of securities fraud directed towards Bath & Body Works and several of its corporate officers and/or directors. Investors who have experienced financial losses during the class period are encouraged to reach out to Pomerantz for potential inclusion in the lawsuit.

Key Details of the Class Action

As investors consider their options, it’s crucial to note the approaching deadline for participation in this class action lawsuit. Anyone who purchased Bath & Body Works securities during the specified class period has until March 16, 2026, to submit a request to be appointed as Lead Plaintiff. Interested individuals can contact Danielle Peyton directly via email at [email protected] or call 646-581-9980 for more information. Those who choose to communicate via email are advised to include their mailing address, phone number, and the number of shares they purchased.

The crux of the class action revolves around allegations that Bath & Body Works may have engaged in deceptive business practices contrary to the interests of its investors. This raises serious concerns regarding the transparency and honesty of the Company's communications to its stakeholders.

Financial Woes Leading to the Lawsuit

The backdrop to this legal action is a series of alarming financial announcements from Bath & Body Works. On August 28, 2025, the Company released its second-quarter results, revealing a dismal earnings per diluted share of $0.30 — a stark decrease of 55.8% compared to the previous year. This performance fell short of the Company’s prior guidance, further aggravating investor concerns.

In addition to the earnings drop, Bath & Body Works reported a severe decline in net income, which fell 57.9% year over year. As a direct consequence of this unfavorable news, stocks plunged by $2.18 per share (approximately 6.9%), settling at $29.36 per share.

The financial difficulties did not end there. On November 20, 2025, the Company once again disappointed investors, citing a 1% decline in revenue — far below the predicted growth range of 1-3%. The news worsened when Bath & Body Works declared a 26% fall in net income to $77 million, coupled with a significant downgrade of its full-year net sales forecast. Instead of expecting a growth of 1.5%-2.7%, the Company anticipated a decline in sales by "high single digits," which catalyzed further stock depreciation. Following this announcement, Bath & Body Works stocks plummeted by $5.22 per share (24.8%) to close at $15.82.

These financial setbacks raise serious questions about corporate governance and the decisions made by the Company's leadership. Investor confidence has been significantly shaken, creating a fertile ground for legal redress as disillusioned stakeholders seek accountability.

About Pomerantz LLP

Pomerantz LLP stands as a reputable name in the realm of corporate, securities, and antitrust litigation in the United States. Established over 85 years ago by the late Abraham L. Pomerantz, who is hailed as a pioneer in securities class actions, the firm has cultivated a legacy of fighting for the rights of investors across various sectors of the market. With a network of offices in major cities, including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, Pomerantz has successfully secured multi-million dollar settlements for its clients, asserting its commitment to justice and investor protection.

Given the legal implications and the evolving nature of this case, affected investors are strongly encouraged to act swiftly and consult with Pomerantz LLP to assess their options and rights under the law. Further information regarding this class action lawsuit can be found on their website, www.pomerantzlaw.com.